CAD 0.01
(N/A%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 28.34 Thousand CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | -100.0% |
2020 | 11.47 Thousand CAD | 59.51% |
2019 | 7192.00 CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | -100.0% |
2005 | 488.00 CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - CAD | 0.0% |
2024 Q1 | - CAD | 100.0% |
2023 Q2 | - CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2023 Q4 | -28.34 Thousand CAD | -200.0% |
2023 Q3 | 28.34 Thousand CAD | 0.0% |
2023 FY | 28.34 Thousand CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 FY | - CAD | -100.0% |
2021 Q3 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2021 Q1 | - CAD | -100.0% |
2020 Q4 | 1526.00 CAD | 15.87% |
2020 Q1 | 6942.00 CAD | -3.48% |
2020 FY | 11.47 Thousand CAD | 59.51% |
2020 Q2 | 1687.00 CAD | -75.7% |
2020 Q3 | 1317.00 CAD | -21.93% |
2019 Q3 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 Q4 | 7192.00 CAD | 0.0% |
2019 FY | 7192.00 CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2007 Q1 | 3599.00 CAD | 0.0% |
2007 Q3 | - CAD | -100.0% |
2007 Q2 | 5581.00 CAD | 55.07% |
2007 FY | - CAD | 0.0% |
2006 Q3 | 295.00 CAD | 100.68% |
2006 FY | - CAD | -100.0% |
2006 Q1 | 148.00 CAD | 0.0% |
2006 Q4 | - CAD | -100.0% |
2006 Q2 | 147.00 CAD | -0.68% |
2005 FY | 488.00 CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Algernon Pharmaceuticals Inc. | - CAD | -Infinity% |
Asep Medical Holdings Inc | 21.14 Thousand CAD | -34.087% |
BetterLife Pharma Inc. | - CAD | -Infinity% |
BioVaxys Technology Corp. | - CAD | -Infinity% |
ChitogenX Inc. | - CAD | -Infinity% |
Rapid Dose Therapeutics Corp. | 1.02 Million CAD | 97.222% |
Defence Therapeutics Inc. | - CAD | -Infinity% |
Entheon Biomedical Corp. | 250.32 Thousand CAD | 88.676% |
Gemina Laboratories Ltd. | - CAD | -Infinity% |
Glow Lifetech Corp. | 43.93 Thousand CAD | 35.476% |
Lexston Life Sciences Corp. | - CAD | -Infinity% |
Pharmala Biotech Holdings Inc. | 532 Thousand CAD | 94.672% |
Doseology Sciences Inc. | 98.52 Thousand CAD | 71.229% |
MYND Life Sciences Inc. | - CAD | -Infinity% |
PharmaTher Holdings Ltd. | - CAD | -Infinity% |
PreveCeutical Medical Inc. | - CAD | -Infinity% |
Telescope Innovations Corp. | 595.39 Thousand CAD | 95.239% |